Lung Cancer

Skip to main content

Lung Cancer

Ramucirumab plus Erlotinib in the Treatment of Patients with NSCLC with EGFR Exon 19 or Exon 21 Mutations

Lung Cancer

First-Line Treatment with Lorlatinib Improves Outcomes Over Crizotinib in Patients with ALK-Positive NSCLC

Lung Cancer

Pralsetinib and Selpercatinib Evaluated as Treatment for Patients with RET Gene Fusion–Positive NSCLC

Lung Cancer

Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC

Lung Cancer

ADJUVANT Study: Quality of Life with Adjuvant Gefitinib versus Vinorelbine plus Cisplatin in Patients with EGFR-Mutant NSCLC

Lung Cancer

Ensartinib in Crizotinib-Resistant, ALK-Positive NSCLC

Lung Cancer

Afatinib + Cetuximab versus Afatinib Alone for the First-Line Treatment of EGFR-Mutant NSCLC (SWOG S1403)

Lung Cancer

Afatinib in Asian and Non-Asian Patients with EGFR Mutation–Positive NSCLC Harboring Uncommon Mutations

Lung Cancer

NEJ009 Study: Gefitinib Alone versus Gefitinib + Chemotherapy for EGFR-Mutant NSCLC

Lung Cancer

GEOMETRY Mono-1 Study: Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC

2
3
4
5
6
7
8

Page 5 of 12
Results 41 - 50 of 116